Excitingly, a clinical trial (NCT05664464) is ongoing, using a combination of gabapentin with a compound to inhibit glutamate secretion and receptor activation in conjunction with radiotherapy to explore the effectiveness of BCAT1 inhibition in glioblastoma patients [61]. The gene discussed is BCAT1; the disease is glioblastoma.